Spending money on end of life drugs will divert resources from prevention and chronic care, MPs toldBMJ 2009; 338 doi: http://dx.doi.org/10.1136/bmj.b647 (Published 18 February 2009) Cite this as: BMJ 2009;338:b647
- Oona Mashta
Measures to improve patients’ access to end of life treatments announced by the National Institute for Health and Clinical Excellence (NICE) will divert resources away from preventive and chronic treatments, says a leading health economist.
Professor Christopher McCabe, chair in health economics at the Institute of Health Sciences at the University of Leeds, told MPs on the Health Select Committee that the move provided incentives for manufacturers that “are not consistent with promoting the health of the UK population.”
After a consultation on appraising end of life medicines, the institute will consider all the benefits when they …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial